Life Sciences Archive » November, 2013

Life Sciences - November, 2013

240 articles

• AstraZeneca, Ranbaxy Can't Ax Claims In Nexium Antitrust MDL
• Biosig Asks High Court To Skip Patent Indefiniteness Case
• DNA Testing Co. Responds To FDA's Demand, Defends Product
• A Snapshot Of In-House Counsel Compliance In 2014
• Drugmaker Wockhardt Faces Yet Another FDA Import Ban
• Stem Cell Patent Case May Limit Standing For USPTO Appeals
• Abbott Accused Of Overcharging Nonprofit $2M For HIV Meds
• Novartis Says Accord Can't Make, Sell Generic Bone Drug
• USTR Says Stance On Drug Patents 'Flexible' In TPP Talks
• Rite Aid Latest Target Of Glucosamine False Ad Litigation
• Female Powerbrokers Q&A: Sidley's Sara Brody
• Female Powerbrokers Q&A: Morgan Lewis' Grace Speights
• Dechert, Sullivan Steer CVS To $2.1B Infusion Biz Buy
• SillaJen Pays $150M For Tumor Treatment Firm
• High Court Birth Control Case Tests Scope Of Biz Rights
• Narrow Critique Does Not Alter EPA Nano Risk Assessment
• Purdue's Bid To Split OxyContin Patent Suit Gets Rejected
• Dental Implant Co. Sanctioned For Destroying Docs In IP Row
• Policy Groups Warn 9th Circ. Of Drug Cleanup Law
• Bristol-Myers Insured Employees Without Consent, Suit Says
• EMA, Drug Giants Join Push To Reform Vaccine Monitoring
• Myriad Says Invitae Is Infringing Cancer Testing Patents
• Hebei Can't Dodge $153M Penalty In Vitamin C Class Action
• Deals Rumor Mill: Repsol, Blackstone, RBS
• Thermo Fisher Sheds 3 Units, Earns EU Nod On Life Tech Buy
• Novartis Can't Apply NJ Punitives Cap In 3 Zometa Suits
• Travelers Says Claims Not Time-Barred In $47M Pfizer Suit
• Elliott Again Lifts Stake In $8.2B Buyout Target Celesio
• Female Powerbrokers Q&A: Mayer Brown's Libby Raymond
• Female Powerbrokers Q&A: Reed Smith's Colleen Davies
• Supreme Court To Review ACA Contraception Mandate
• Savient's Unsecured Creditors Blast Cash-Collateral Motion
• FDA Scrutiny Looms For Unapproved Research Tests
• Pfizer Escapes FCA Suit Over Anti-Fungal Drug Promotions
• DNA Testers On Notice As FDA Warns Wife Of Google's Brin
• Vitamin Shoppe Sues Seeger Weiss Over Class Action Site
• Defendant In BigLaw Insider Trading Case Mulls Settlement
• FDA Loosens Restrictions On GSK's Avandia
• AIG Must Pay $3.75M To Cover Ad Injury Claims, Jury Says
• Shire Targets Apotex Over Plan For Generic ADHD Drug
• Texas High Court Rejects Medicaid Rate Challenge
• Teva, Mylan Reach Deal Ending MS Drug Litigation In Europe
• Medical Device Co. Says Exec Misappropriated Trade Secrets
• Insurer Disputes Coverage For NECC-Linked Compounder
• Deals Rumor Mill: Blackstone, Glencore, Equity Residential
• Expect More Rulings Invalidating Patents Under Section 101
• Female Powerbrokers Q&A: Hogan Lovells' Janet McDavid
• Female Powerbrokers Q&A: DLA Piper's Lisa Haile
• Cadence Prevails Against Exela In Generic Ofirmev Row
• Ex-Lilly Sales Rep Wants Contract Case In Fla. State Court
• Merck Says Claims Too Varied For Cert. In $100M Bias Suit
• Canada High Court OKs Ban On Pharmacy-Brand Generics
• Judge Backs Jury Finding In J&J Body Powder Cancer Suit
• FDA Calls Out Amgen Over Misleading Anemia Drug Claims
• Shandong Weigao Inks $312M Deal To Sell Biosensors Stake
• Taylor English Lands Bryan Cave Product Liability Pro
• Fed. Circ. Reverses Rejection Of Psoriasis Drug Patent
• Female Powerbrokers Q&A: Norton Rose's Jane Smith
• Female Powerbrokers Q&A: Jones Day's Mary Ellen Powers
• Deals Rumor Mill: Time Warner, BC Partners, Spotify
• J&J Takes Innovative, If Pricey, Route To Ending Hip Suits
• China Must Double-Down On Trade Secret Protection
• In New FCA World, Anyone's A Whistleblower
• Reorganized Rotech Says Baker & McKenzie Lied To Court
• Health Fund Fights Dismissal Of GSK Copay Coupon Suit
• Axinn Veltrop Adds IP Litigator From Curtis Mallet-Prevost
• FDA Rips 'Troubling' Drug Promo In Repeat Warning Letter
• Female Powerbrokers Q&A: Weil's Mindy Spector
• Female Powerbrokers Q&A: Hunton & Williams' Sandy Collins
• Hologic Opts For Poison Pill After Icahn Discloses Stake
• Philips, Zoll Can't Escape Defibrillator Patent Suits
• Doryx Indirect Purchasers Denied Cert. In Warner Antitrust Suit
• Even $2.5B Can't Buy An End To J&J's Hip Troubles
• GNC Hit With Suit Linking Supplement To Hepatitis
• 25 Drug Cos. Put Up $88M To Escape Price-Rigging Suits
• How Some Attorneys Succeed Where The 'Elite' Fail
• In-House Labs Require Health Investor Due Diligence
• FDA Restricts Use Of 2 Astellas Heart Test Drugs
• Spanish Court Finds Grunenthal Liable In Thalidomide Case
• Female Powerbrokers Q&A: Morgan Lewis' Jami McKeon
• Female Powerbrokers Q&A: Sidley's Sara Gourley
• US Pushing Hatch-Waxman Protections In TPP
• Bayer Pay-For-Delay Deal A Taste Of Post-Actavis Climate
• $25M Hydroxycut Settlement Denied In False Ad MDL
• J&J Unit Hit With Suit Over Rheumatoid Arthritis Drug
• 5 Ways To Make The FCA Fairer And More Effective
• Mapping The Divide Over Stream Of Commerce Doctrine
• FTC Eyes Disgorgement In Cephalon Pay-For-Delay Fight
• Horizon Pays $35M For AstraZeneca's Arthritis Drug Rights
• 9th Circ. Upholds Dismissal Of Melatonin Brownie Claims
• DSM Inks $2.6B Spinoff Deal With JLL Partners
• BMS Says Use Of Private Attys In Miss. Plavix Case Is Illegal
• Daiichi Sankyo Escapes Antitrust MDL Over Generic Lipitor
• Female Powerbrokers Q&A: Miller Canfield's Megan Norris
• Expert Deposition Tips For Young Lawyers
• Female Powerbrokers Q&A: Buchanan's Wendy Newton
• J&J To Pay $2.5B To Settle Hip Implant Litigation
• Senate Approves Drug Compounding Reform Bill
• Janssen Owes Family $10M In Topamax Suit, Jury Says
• Bayer's $74M Cipro Pay-For-Delay Deal Approved In Calif.
• 3rd Circ. Affirms Plavix Injury Dismissals in NJ
• J&J Rips Derivative Suit Over Ex-CEO's $30M Salary
• CareFusion Pays GE $500M For Medical Disposables Biz
• NY Doc Says Remington Ripped Off His Hair-Removal Patents
• US Agents Seize $2M In DMAA Supplements
• Supreme Court Roundup: 2012 To The Term Ahead
• 9 Firms Surge Onto GC All-Stars List
• Skadden The Firm Most Loved By General Counsel
• Fed. Circ. Upholds $10M Medtronic Patent Verdict
• 8th Circ. Returns Boston Scientific Mesh Suits To Fed. Court
• Texas, Mich. Zoloft Suits Show No Deception, Pfizer Says
• 9 Top Firms Tumble From List Of GC Favorites
• FDA Asks Texas Compounder To Halt Sterile Drug Production
• FDA Lays Out Drug Naming Standards For Advertisements
• 3 Pharmacists Suspended For Painkiller Distribution Ring
• Economics Of Irreparable Harm In Pharma Patent Litigation
• High Court Accepts Chesley's Resignation From Bar
• GCs Name Most Arrogant Law Firms
• More Firms Get Serious About Keeping GCs Happy
• When It Comes To Law Firms, Size Doesn't Matter, GCs Say
• Female Powerbrokers Q&A: Irell & Manella's Andra Greene
• Female Powerbrokers Q&A: Thompson & Knight's Emily Parker
• Biosimilar-Substitution Restrictions Head To Pa. Senate
• Appeal In Reglan Preemption Row Blasted In Pa. High Court
• FDA Trans Fats Decision Could Affect Other Ingredients
• Fed. Circ. Affirms Invalidity Ruling In Prosthetics IP Dispute
• Female Powerbrokers Q&A: Quarles & Brady's Kim Johnson
• Female Powerbrokers Q&A: Duane Morris' Dominica Anderson
• PE Owners Mull $1.2B Sale Of Medpace Clinical Research Unit
• Obama Names ACA Supporter As Surgeon General
• FDA Calls For Antiseptic Label Changes To Limit Risk
• Takeaways From Stryker's FCPA Settlement
• Nexium Buyers Win Class Cert In AstraZeneca Antitrust MDL
• Doc Block: Ex-SAC Trader Slams Feds In Discovery Row
• Ex-FDA Heads Want FDA To Cut Antibiotic Use In Livestock
• Nelson Mullins Snags Health Care Pros From LeClairRyan
• Novartis Fails To Wipe Out $1.3M Zometa Verdict
• Actavis Testosterone Drug Flouts 6 Patents, Eli Lilly Says
• High Court Snubs Teva Bid To Stay Copaxone Invalidity Ruling
• Elliott Pumps Up Stake In $8.2B Takeover Target Celesio
• Pay-For-Delay Remains Top Priority For Ramirez's FTC
• FDA Floats Plan For Streamlined Device Evaluation
• NJ Men Cop To Insider Trading With Celgene, Stryker Stock
• 1st Biosimilars Act Ruling May Limit Patent Challenges
• Eli Lilly, Others Urge 6th Circ. To Toss Darvocet Appeal
• Ad Watchdog Wrong On Sleep Aid Claims, Review Panel Finds
• Reorganized Rotech Objects To $1M Baker & McKenzie Fees
• Suits Target Endo, Actavis Over Lidoderm Pay-For-Delay
• A Season Of Uncertainty In GMO Labeling
• AmerisourceBergen Beats Online Posters' Bid To Hide IDs
• Counterfeit Male Enhancement Drug Poses Risks, FDA Warns
• J&J To Pay $4B To Settle Hip Implant Suits
• Boehringer Sued Over $120M Pay-For-Delay On Stroke Drug
• J&J Trying To Back Out Of 77 Risperdal Deals, Plaintiffs Say
• FDA Rips Aegerion Exec For Drug Promo Claims On CNBC
• Pressured By Stockholders, Struggling Solta May Seek Sale
• Pfizer Settles Retail Pharmacies' Antitrust Claims
• Epstein Becker Green Snags IP, Life Sciences Pro
• 4 More Reforms That Would Improve FCA
• Deals Rumor Mill: TPG Capital, Adcock, Carlos Slim
• Teva Agrees To Pay $720M In Israeli Tax Agreement
• McNeil Asks Pa. Appeals Court To Boot $10M Motrin Verdict
• There May Be A Paradigm Shift In Generic Drug Labeling
• When Transfer Of Drug Patent Rights Is Reportable To FTC
• FDA Labeling Rule Creates Liability Risk For Generics Cos.
• Magistrate OKs DePuy Trade Secrets Claims Against Reps
• Dr. Oz Can Testify In Medtronic's Heart Valve Patent Suit
• Despite $2B Deal, J&J's Risperdal Fight Rages On In Pa.
• Lilly Sues Slew Of Insurers Over Brazil Tort Claims
• Amarin Appeals FDA Ruling On Fish Oil Drug's Expansion
• Law360 MVP Awards Go To Legal Top Guns From 58 Firms
• Deals Rumor Mill: AstraZeneca, ICBC, Johnson & Johnson
• Pfizer, Mylan Settle With Mass. AG Over EpiPen Commercial
• Brown Rudnick Plucks Life Sciences Expert From Bingham
• FDA Rule Would Allow Generics Makers To Update Labels
• Personalized Medicine Providers, FDA Has Your Back
• GNC Shakes False Label Class Action Over Meal Bars
• Thermo Fisher Makes Commitments To EU In Life Tech Buy
• J&J To Pay $400M Over Criminal Charge In Risperdal Case
• FTC Patent License Rule Sure To Annoy Drugmakers
• Wyeth, Elan Investors Slam $1.2B SAC Plea Bargain
• Fen-Phen Plaintiffs Cut From Napoli Bern Settlement Suit
• Iclusig Deaths Won't Stall FDA's Speedier Drug Approvals
• Covington Guides Salix's $2.6B Gastro Drugmaker Buy
• Amarin Accused Of Pumping Up Stocks Before FDA Snub
• Carving A Path Around 9th Circ.'s Gerber Decision
• Travelers Receives Sharp Rebuke In Heparin Discovery Fight
• Calif. Supplement Maker Hawked Absent Ingredient, Suit Says
• FDA Needs Rule Change For DMAA Crackdown, Suit Says
• USPTO's Power To Nix Verdicts Ripe For Supreme Court
• FTC Redefines Which Drug Patent Deals Need Antitrust OK
• McKesson Inks $14M Deal In Wis. Drug Price-Rigging Suit
• EPA Sues Dow, Exxon, Others For NJ Superfund Site Cleanup
• Drugmakers Take Reglan Preemption Appeal To Pa. High Court
• Fed. Circ. Axes E8 Pharmaceuticals' Gene Testing IP Claims
• Sandoz Appeals Eye Drug Patent Verdict To Fed. Circ.
• Elliott Unveils 10% Stake In $8.2B Takeover Target Celesio
• Ex-NFL Doc Ends $2M Indemnity Suit Against Smith & Nephew
• 'Rough Justice' Is Not Justice
• Why High Stakes Legal Failures Happen
• Insurers Settle Alaven's $10M Reglan Injury Coverage Suit
• Ballard Spahr Lands IP, Antitrust Aces For Atlanta, DC
• Fed. Circ. Won't Review Disposal Of Baxter's $23.5M IP Award
• Bristol-Myers Wins Patent Fight Over Generic HIV Drug
• Justices Wary Of Putting Burden Of Proof On IP Licensees
• Teva Asks Supreme Court For Stay On MS Drug Patent Ruling
• Allergan Triumphs In 'Botox' Trademark Dispute
• Iowa Telemedicine Abortion Ban Delayed By Judge
• Deals Rumor Mill: NYSE Euronext, One Equity Partners, KKR
• Pfizer Beat Sanofi To Isolated DNA Patent, Fed. Circ. Says
• Citing $2B J&J Deal, Pa. Pol Floats State False Claims Act
• Bard Denied Atty Fees For Dropped Vaginal Mesh Bellwether
• State Claims Reinstated In Novartis Elidel FCA Suit
• Epstein Becker Green Brings On FDA Pro From Hodgson Russ
• Skadden Steers Endo's $1.6B Paladin Labs Buy
• Illumina Can't Escape $115M Judgment In Syntrix Patent Suit
• Chief Justice Roberts Turns Up The Heat On Cy Pres Pacts
• With $2B J&J Deal, FCA Proves It's Still The Anti-Fraud King
• Justices May Raise Bar For Licensees Challenging Patents
• J&J's $2.2B Deal A Last Hurrah For Off-Label Crackdown
• Tomato Extract Maker Drops IP Suit Against Competitor
• Fed. Circ. Nixes Injunction On J&J Rival's Glucose Strips
• Roche Inks $549M Deal To License 'Superbug' Antibiotic
• Justices Won't Touch Facebook's $9.5M 'Beacon' Privacy Deal
• Takeda Triumphs In Suits To Block Generic Dexilant
• High Court Won't Hear Okla. Appeal Over Abortion-Drug Law
• Finding The Sweet Spot In Evaporated Cane Juice Cases
• Supreme Court Trends In Federal Preemption
• J&J Inks $2.2B Settlement For Off-Label Marketing, Kickbacks
• Otsuka Says Wockhardt's ANDA Infringes Abilify Patent
• 3 Pitfalls Posed By Over-The-Counter Drug Recalls
• Syringe Maker Faces Securities Suit Amid Whistleblower Row
• Elan Investors Say SAC Should Admit Insider Trading In Plea
• Supreme Court Asked To Take Up Lupron Labeling Suit
• Elan Win In IP Feud Over Skelaxin Confirmed By Judge
• OrbiMed Forms $735M VC Fund To Invest In Health Industry
• Warner Chilcott Sues Mylan To Block Generic Lo Loestrin
• New Prop 65 Is A Relief For Calif. Manufacturers
• Fed. Circ. Ruling Provides Guidance On 'Reason To Combine'
• Ariad Opts For Poison Pill After Hedge Fund Buy-In